Why Regeneron Investors Shouldn't Fear Its Patent Cliff | The Motley Fool

Patents, Intellectual Property News

Patents on primary revenue driver EYLEA are set to expire soon. Expanding indications for existing products will pick up the slack. Oncology pipeline ...

Related articles